Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Dynatrace Is Said to Offer Zero Coupon on Exchangeable Bond
• Global debt issuance falls 16% in latest week, Goldman says